ImmuPharma plc (AIM:IMM)
London · Delayed Price · Currency is GBP · Price in GBX 11.13
+3.07 (38.03%)
Sep 9, 2025, 6:24 PM GMT+1
ImmuPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
40.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 118.35K | -8.32K | -6.57% |
| Dec 31, 2020 | 126.67K | 48.74K | 62.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
ImmuPharma News
- 1 day ago - AIM Market Roundup: ImmuPharma, Rockfire Resources, Likewise - The Armchair Trader
- 7 days ago - AIM Market Roundup: Dewhurst, Metir, Tertiary Minerals - The Armchair Trader
- 8 days ago - AIM Market Roundup: ImmuPharma, N4 Pharma, Versarien - The Armchair Trader
- 4 weeks ago - AIM Market Roundup: Catenai, Europa Oil & Gas, Faron Pharma - The Armchair Trader
- 4 weeks ago - FTSE Rises as Investors Eye Tariff Deadline - Investomania
- 6 months ago - FX positioning info - Net speculative EUR longs surged in a sharp rise from previous week - Forexlive
- 6 months ago - Data show speculative traders have flipped from a net short to a net long position on euro - Forexlive
- 8 months ago - AIM Market Roundup: Immupharma, Poolbeg, Xeros - The Armchair Trader